We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Adverse events during the titration phase of interferon-beta in remitting-relapsing multiple sclerosis are not predicted by body mass index nor by pharmacodynamic biomarkers.
- Authors
Muñoz, Delicias; Escartín, Antonio; Dapena, Dolores; Coret, Francisco; Fernández-Uría, Dionisio; Pérez, Domingo; Casanova, Bonaventura; Guijarro-Castro, Cristina; Munteis, Elvira; del-Campo Amigo, María; Pego, Robustiano; Calles, Carmen; García-Rey, César; Monsalve, Nuria; Sánchez-Matienzo, David
- Abstract
Background: This study aimed to correlate body mass index or biomarkers with the frequency of common adverse events (AEs) with subcutaneous IFN β-1a during treatment titration in patients with relapsing-remitting multiple sclerosis previously naïve to IFN β. Methods: Eighty-four patients (66.3% females) were followed up during 8 weeks, 25.3% were overweight and 14.5% were obese. Results: Biomarkers steadily increased during all study period by 45.3% for β2-microglobulin, 262.8% for olygoadenylate synthetase-1, and 92.8% for neopterin. Overall AE reporting did not vary with the dose or treatment duration. Conclusions: BMI was not predictive of increased risk for AEs. Biomarkers did not discriminate on the frequency of any AE either.
- Subjects
VOLUMETRIC analysis; INTERFERONS; DRUG side effects; MULTIPLE sclerosis treatment; DISEASE relapse; BODY mass index; PHARMACODYNAMICS; BETA 2-microglobulin
- Publication
BMC Neurology, 2013, Vol 13, Issue 1, p1
- ISSN
1471-2377
- Publication type
Article
- DOI
10.1186/1471-2377-13-82